Education

Personal Finance How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

InnoCare Pharma Ltd. (HK:9969)

HKEX:9969

9969

InnoCare Pharma Ltd.

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Holding HK:9969?

Track your performance easily

Link Broker

InnoCare Pharma Ltd. (9969) Stock Price & Analysis

0 Followers

9969 Stock Chart & Stats

Advanced Chart >

Day’s RangeHK$0 - HK$0

52-Week RangeHK$4.03 - HK$7.92

Previous CloseHK$6.52

Volume4.21M

Average Volume (3M)6.68M

Market Cap

HK$9.76B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Mar 20, 2025

EPS Estimate

-HK$0.09

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding249,728,111

10 Day Avg. Volume7,462,510

30 Day Avg. Volume6,680,482

Standard Deviation0.17

R-Squared0.24

Alpha0.00403

Financial Highlights & Ratios

Price to Book (P/B)335.50

Price to Sales (P/S)12.59

Price to Cash Flow (P/CF)-29.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$8.80

Price Target Upside34.97% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

InnoCare Pharma Ltd. News

PremiumCompany Announcements

InnoCare Pharma Updates on Funds Utilization Strategy

11d ago

9969

PremiumCompany Announcements

InnoCare Announces Breakthrough Psoriasis Drug Results

1M ago

9969

PremiumCompany Announcements

InnoCare Pharma Reveals Board Structure

2M ago

9969

PremiumCompany Announcements

InnoCare Pharma Announces Board Reshuffle

2M ago

9969

PremiumCompany Announcements

InnoCare Advances MS Treatment into Phase 3 Trials

3M ago

9969

PremiumCompany Announcements

InnoCare Pharma Announces Strong Mid-Year Growth

3M ago

9969

PremiumCompany Announcements

InnoCare Pharma Sets Date for Financial Update

4M ago

9969

PremiumCompany Announcements

InnoCare Pharma Awards Employees with Share Scheme

5M ago

9969

See More HK:9969 News >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

1.66% Mutual Funds

― Other Institutional Investors

96.63% Public Companies and

Individual Investors

Detailed Ownership Overview >

9969 FAQ

What was InnoCare Pharma Ltd.’s price range in the past 12 months?

InnoCare Pharma Ltd. lowest stock price was HK$4.03 and its highest was HK$7.92 in the past 12 months.

What is InnoCare Pharma Ltd.’s market cap?

Currently, no data Available

When is InnoCare Pharma Ltd.’s upcoming earnings report date?

InnoCare Pharma Ltd.’s upcoming earnings report date is Mar 20, 2025 which is in 118 days.

How were InnoCare Pharma Ltd.’s earnings last quarter?

InnoCare Pharma Ltd. released its earnings results on Nov 11, 2024. The company reported -HK$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.011.

Is InnoCare Pharma Ltd. overvalued?

According to Wall Street analysts InnoCare Pharma Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does InnoCare Pharma Ltd. pay dividends?

InnoCare Pharma Ltd. does not currently pay dividends.

What is InnoCare Pharma Ltd.’s EPS estimate?

InnoCare Pharma Ltd.’s EPS estimate is -HK$0.09.

How many shares outstanding does InnoCare Pharma Ltd. have?

InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding.

What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?

InnoCare Pharma Ltd. reported an EPS of -HK$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.259%.

Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?

Currently, no hedge funds are holding shares in HK:9969

---

InnoCare Pharma Ltd. Stock Smart Score

Unlock Smart Score

Analyst Consensus

Moderate Buy

Average Price Target:
HK$8.80 (34.97% Upside)

Technicals

Fundamentals

Return on Equity

-5.28%

Trailing 12-Months

Asset Growth

-2.74%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

InnoCare Pharma Ltd.

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. Its commercial drug candidate is Orelabrutinib and clinical-stage drug candidates are ICP-192, ICP-105, ICP-723, and others.

---

9969 Stock 12 Month Forecast

Average Price Target

HK$8.80

▲(34.97% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"HK$4","9":"HK$9","5.25":"HK$5.25","6.5":"HK$6.5","7.75":"HK$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$8.80</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$8.80</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,5.25,6.5,7.75,9],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"Nov<br/>2024","25":"Nov<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.58,6.750769230769231,6.921538461538462,7.092307692307693,7.263076923076923,7.433846153846154,7.604615384615385,7.775384615384616,7.946153846153846,8.116923076923078,8.287692307692309,8.458461538461538,8.62923076923077,{"y":8.8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.58,6.750769230769231,6.921538461538462,7.092307692307693,7.263076923076923,7.433846153846154,7.604615384615385,7.775384615384616,7.946153846153846,8.116923076923078,8.287692307692309,8.458461538461538,8.62923076923077,{"y":8.8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.58,6.750769230769231,6.921538461538462,7.092307692307693,7.263076923076923,7.433846153846154,7.604615384615385,7.775384615384616,7.946153846153846,8.116923076923078,8.287692307692309,8.458461538461538,8.62923076923077,{"y":8.8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.13,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.06,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":8.11,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.64,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.95,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.3,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":7.02,"date":1700179200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.3,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.09,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.17,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.87,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.58,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

RemeGen Co. Ltd. Class H

―

9926

Akeso, Inc.

―

1699

China Putian Food Holding Ltd.

―

2222

NVC International Holdings Ltd.

―

Compare HK:9969 Stocks >

Best Analysts Covering 9969

1 Year

Chris LuiJefferies

1 Year Success Rate

1/3 ratings generated profit

1 Year Average Return

-6.67%

reiterated a buy rating 29 days ago

Copying Chris Lui's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -6.67% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing